热疗联合FOLFOX4方案治疗晚期胃癌疗效观察

目的研究FOLFOX4方案联合热疗治疗晚期胃癌的疗效和不良反应。方法 70例患者随机分为化疗组(35例)、联合组(35例)。化疗组接受FOLFOX4方案化疗,每3周重复1次,21 d为一周期;联合组在FOLFOX4方案化疗的同时给以热疗,热疗每次60 min,每周2次。2周期后评价2组疗效。结果联合组患者完全缓解(complete response,CR)5例、部分缓解(partial response,PR)16例,有效率(CR+PR)60.00%;化疗组患者CR 0例、PR 10例,有效率(CR+PR)28.57%。治疗后联合组患者血清肿瘤抗原CEA、CA50、CA12-5、CA153、CA19-9显著低于化疗组(P<0.05)。联合组与化疗组患者的不良反应主要为胃肠反应和骨髓抑制,但两组不良反应发生率差异无统计学意义(P>0.05)。结论热疗联合FOLFOX4方案化疗应用于晚期胃癌疗效肯定,不良反应能耐受,值得临床推广应用。

Efficacy of hyperthermia combined with FOLFOX4 chemotherapy in treatment of advanced gastric cancer

Objective To evaluate the clinical effect and toxicity of hyperthermia combined with FOLFOX4 regimen for patients with advanced gastric cancer. Methods Total 70 patients with advanced gastric cancer were divided randomly into chemotherapy group and hyperthermia plus chemotherapy group with 35 cases in each group. Patients in chemotherapy group were treated with FOLFOX4 regimen, repeated every 3 weeks as one cycle. The same chemotherapy regimen was given to patients in hyperthermia plus chemotherapy group, and hyperthermia was applied for 60 min, twice a week. Efficacy was evaluated after 2 chemotherapy cycles. Results In the hyperthermia plus chemotherapy group, complete responses (CR) were observed in 5 cases, partial responses (PR) in 16 cases with an overall response rate od 60. 0%. In the chemotherapy group, no CR, PR in 10 cases with an overall respons rate of 28. 6% . The main toxicity was nausea/vomiting and bone marrow suppression. Serum CEA, CA50, CA12 - 5, CA153 and CA19 - 9 levels were significantly lower in hyperthermia plus chemotherapy group than those in chemotherapy group after treatment (P < 0. 05) . Conclusion The hyperthermia combined with FOLFOX4 regimen is effective and tolerable in advanced gastric cancer therapy.